(Q34398065)

English

New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease (English)

1 reference

Europe PubMed Central

1 August 2017

1 reference

based on heuristic

inferred from title

atherosclerosis

1 reference

based on heuristic

inferred from title

fatty liver disease

0 references

non-alcoholic fatty liver

1 reference

based on heuristic

inferred from title

metabolic dysfunction–associated steatotic liver disease

1 reference

based on heuristic

inferred from title

atherogenic dyslipidemia

1 reference

based on heuristic

inferred from title

Amirhossein Sahebkar

1

object named as

Amirhossein Sahebkar

1 reference

Europe PubMed Central

1 August 2017

3

object named as

Gerald F Watts

1 reference

Europe PubMed Central

1 August 2017

author name string

Gerard T Chew

2

1 reference

Europe PubMed Central

1 August 2017

language of work or name

0 references

publication date

16 January 2014

1 reference

Europe PubMed Central

1 August 2017

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

1 August 2017

15

1 reference

Europe PubMed Central

1 August 2017

493-503

1 reference

Europe PubMed Central

1 August 2017

4

1 reference

Europe PubMed Central

1 August 2017

Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Relation of hepatic steatosis to atherogenic dyslipidemia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Role of ezetimibe in non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

PPAR agonists for the treatment of cardiovascular disease in patients with diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Fibrate therapy and circulating adiponectin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Fat and beyond: the diverse biology of PPARgamma

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

The safety of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Safety issues and prospects for future generations of PPAR modulators

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Skeletal consequences of thiazolidinedione therapy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Peroxisome proliferator-activated receptor δ: a multifaceted metabolic player

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monother

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Diabetes: New conductors for the peroxisome proliferator-activated receptor γ (PPARγ) orchestra

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.876992

21 January 2018

Identifiers

10.1517/14656566.2014.876992

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34398065&oldid=1598605194"